Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$373.7m

Entrada Therapeutics Valuation

Is TRDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TRDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TRDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRDA?

Key metric: As TRDA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TRDA. This is calculated by dividing TRDA's market cap by their current earnings.
What is TRDA's PE Ratio?
PE Ratio5.7x
EarningsUS$65.63m
Market CapUS$373.72m

Price to Earnings Ratio vs Peers

How does TRDA's PE Ratio compare to its peers?

The above table shows the PE ratio for TRDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average46.7x
SPRY ARS Pharmaceuticals
151.6x55.8%US$1.2b
RIGL Rigel Pharmaceuticals
20.6x20.8%US$360.8m
PTGX Protagonist Therapeutics
11.7x-2.0%US$3.2b
AGIO Agios Pharmaceuticals
2.7x-23.8%US$1.8b
TRDA Entrada Therapeutics
5.7x-37.0%US$373.7m

Price-To-Earnings vs Peers: TRDA is good value based on its Price-To-Earnings Ratio (5.7x) compared to the peer average (46.7x).

Price to Earnings Ratio vs Industry

How does TRDA's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AGIO Agios Pharmaceuticals
2.7x-23.8%US$1.79b
INBX Inhibrx Biosciences
0.1xn/aUS$207.73m
CHRS Coherus BioSciences
4.2x-30.7%US$119.37m
CTMX CytomX Therapeutics
1.7x-45.7%US$53.41m
TRDA 5.7xIndustry Avg. 20.4xNo. of Companies11PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TRDA is good value based on its Price-To-Earnings Ratio (5.7x) compared to the US Biotechs industry average (20.4x).

Price to Earnings Ratio vs Fair Ratio

What is TRDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRDA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.7x
Fair PE Ratio6.5x

Price-To-Earnings vs Fair Ratio: TRDA is good value based on its Price-To-Earnings Ratio (5.7x) compared to the estimated Fair Price-To-Earnings Ratio (6.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TRDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.49
US$25.43
+142.4%
16.1%US$30.00US$20.00n/a4
Mar ’26US$11.94
US$25.43
+113.0%
16.1%US$30.00US$20.00n/a4
Feb ’26US$13.44
US$26.43
+96.6%
14.1%US$29.00US$20.00n/a4
Jan ’26US$17.29
US$26.43
+52.8%
14.1%US$29.00US$20.00n/a4
Dec ’25US$19.89
US$25.57
+28.6%
15.4%US$28.71US$20.00n/a3
Nov ’25US$17.60
US$23.90
+35.8%
18.6%US$28.71US$18.00n/a3
Oct ’25US$16.00
US$23.90
+49.4%
18.6%US$28.71US$18.00n/a3
Sep ’25US$17.70
US$23.90
+35.0%
18.6%US$28.71US$18.00n/a3
Aug ’25US$15.96
US$23.20
+45.3%
16.1%US$26.59US$18.00n/a3
Jul ’25US$14.32
US$23.20
+62.0%
16.1%US$26.59US$18.00n/a3
Jun ’25US$15.47
US$23.86
+54.3%
11.8%US$26.59US$20.00n/a3
May ’25US$13.25
US$21.00
+58.5%
4.8%US$22.00US$20.00n/a2
Apr ’25US$13.76
US$21.00
+52.6%
4.8%US$22.00US$20.00n/a2
Mar ’25US$13.73
US$21.00
+52.9%
4.8%US$22.00US$20.00US$11.942
Feb ’25US$14.77
US$21.00
+42.2%
4.8%US$22.00US$20.00US$13.442
Sep ’24US$15.41
US$21.50
+39.5%
16.3%US$25.00US$18.00US$17.702
Aug ’24US$16.94
US$21.50
+26.9%
16.3%US$25.00US$18.00US$15.962
Jul ’24US$15.14
US$21.50
+42.0%
16.3%US$25.00US$18.00US$14.322
Jun ’24US$11.44
US$21.50
+87.9%
16.3%US$25.00US$18.00US$15.472
May ’24US$12.76
US$21.50
+68.5%
16.3%US$25.00US$18.00US$13.252
Mar ’24US$12.25
US$23.50
+91.8%
23.4%US$29.00US$18.00US$13.732
Analyst Price Target
Consensus Narrative from 4 Analysts
US$25.43
Fair Value
58.7% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 17:46
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entrada Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Boobalan PachaiyappanH.C. Wainwright & Co.